Dose-escalation Study of Birinapant and Pembrolizumab in Solid Tumors

NCT02587962 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

TERMINATED

Status

34

Enrollment

INDUSTRY

Sponsor class

Stopped Based on a futility analysis, the data monitoring committee recommended to stop enrollment.

Conditions

Solid Tumors

Interventions

DRUG: Birinapant
DRUG: Pembrolizumab

Sponsor

Medivir

Collaborators

[object Object]